WATERTOWN, Mass--VI Technologies (VITEX) has announced the appointment of Joseph M. Limber to its Board of Directors.
Limber, currently the president and CEO of ACLARA BioSciences, Inc., has 25 years of biotechnology and pharmaceutical management experience.
VITEX is a biotechnology company responsible for developing products that inactive and remove pathogens in blood. Using nucleic acid chemistry, the company produced Inactine Pathogen Inactivation. The technology inactivates blood-borne viruses and bacteria and is in Phase II of clinical trials.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.